Actively Recruiting
Effect of Vitamin D3 Supplementation on Brain Waves in Male Parkinson's Disease Patients With Hypovitaminosis D : A Quantitative Electroencephalogram Analysis
Led by Bangladesh Medical University · Updated on 2025-07-31
15
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying whether vitamin D3 supplements can affect brain waves in male patients with Parkinson's disease who have low vitamin D levels. This experimental self-controlled trial focuses on men aged 51 to 70 with Parkinson's disease up to stage 3 and confirmed vitamin D deficiency. The goal is to see if taking vitamin D3 changes brain electrical activity as measured by quantitative electroencephalogram (QEEG). Participants will take a vitamin D3 capsule orally at a dose of 50,000 IU once a week for 8 weeks. Before starting the supplementation, their vitamin D levels and brain activity will be measured, and these assessments will be repeated after the 8-week treatment period. Brain waves will be recorded using a specialized EEG device analyzing various frequency bands including alpha, beta, theta, and delta. During the study, participants will visit the medical university for evaluations including blood tests for vitamin D levels and EEG recordings both before and after the supplementation period. Researchers will analyze changes in brain wave power and frequency using statistical methods. Participants are asked to bring back empty vitamin D capsule strips for adherence monitoring. The study is designed to last just over eight weeks from the start of treatment to final evaluation.
CONDITIONS
Brief Title
Effect of Vitamin D3 on Brain Waves in Male Parkinson's Patients With Low Vitamin D: A qEEG Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male patients with Parkinson's disease up to stage 3 according to Hoehn and Yahr scale
- Age between 51 and 70 years
- Body mass index (BMI) between 18.5 and 24.9 kg/m2
- Hypovitaminosis D with serum 25(OH)D level below 30 ng/ml
- Patients currently on Levodopa therapy
You will not qualify if you...
- Currently taking vitamin D3 supplements
- Using medications or substances that affect neuronal excitability or EEG, such as sedatives, antidepressants, antipsychotics, or alcohol
- Having neurological disorders like migraine or epilepsy
- Having cardiovascular diseases including myocardial infarction, hypertension, arrhythmia, or heart failure
- Having respiratory disorders such as bronchial asthma or COPD
- Having psychiatric illnesses such as schizophrenia, major depression, bipolar disorder, or severe dementia
- Biochemical evidence of hypercalcemia, renal insufficiency, liver diseases, or uncontrolled endocrine disorders including diabetes mellitus, hypothyroidism, or hyperthyroidism
- Active smoker
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 8 weeks
Participants receive vitamin D3 supplementation orally at a dose of 50,000 IU weekly for 8 weeks.
Weekly visits for 8 weeks
Duration - 1 to 2 weeks
After the treatment period, participants undergo reassessment including serum vitamin D level and EEG recording to evaluate changes in brain electrical activity.
1 visit (in-person)
Trial Site Locations
Total: 1 location
1
Bangladesh medical university
Dhaka, Shahbag, Bangladesh, 1000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here